Korean College of Rheumatology Biologics and Targeted Therapy Registry

Summary

We established a nationwide biologics and targeted synthetic DMARDs registry (in the form of an inception cohort) to study the safety profiles in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis patients receiving biologics or targeted synthetic DMARDs. As this registry is to observe the "real world" use of anti-rheumatic treatments under routine clinical practice, no hypothesis to prove is planned.

Eligibility

Inclusion Criteria:

* Patients diagnosed with RA, AS or PsA
* RA deemed by their rheumatologist to require treatment with a biologic or targeted synthetic DMARDs or a conventional DMARD(s)
* AS or PsA patients who are to initiate, restart or switch to a biologic agent or a targeted synthetic DMARD
* Patients who provide a written consent of participating in this registry (data collection and review).

Exclusion Criteria:

* RA, AS, PsA patients who are already on biologics or targeted synthetic DMARDs upon screening

Conditions4

Browse More Trials